Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A James M Daveson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Best Practice & Research. Clinical Gastroenterology|June 19, 2012
Small bowel endoscopy and coeliac diseaseA James M Daveson, Robert P Anderson
Alimentary Pharmacology & Therapeutics|August 14, 2019
Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac diseaseKenneth E Truitt, A James M Daveson, Hooi C Ee, et al.
Internal Medicine Journal|December 29, 2022
High incidence of inflammatory bowel disease in Northern Australia: a prospective community population-based Australian incidence study in the Mackay-Isaac-Whitsunday regionAmanda Flanagan, Susan M Allsopp, Sam A O'Connor, et al.
Alimentary Pharmacology & Therapeutics|November 27, 2019
Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac diseaseA James M Daveson, Jason A Tye-Din, Gautam Goel, et al.
BMC Medicine|November 26, 2020
Patient factors influencing acute gluten reactions and cytokine release in treated coeliac diseaseJason A Tye-Din, A James M Daveson, Kaela E Goldstein, et al.
Gastroenterology|March 28, 2026
A Randomized Double-Blind, Placebo-Controlled Dose-Response Study to Assess the Gluten Threshold Dose in Celiac DiseaseA James M Daveson, Emma Craig, Alina Vitak, et al.
Ebiomedicine|December 2, 2017
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 StudyA James M Daveson, Hooi C Ee, Jane M Andrews, et al.
Alimentary Pharmacology & Therapeutics|September 5, 2019
Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac diseaseJason A Tye-Din, A James M Daveson, Hooi C Ee, et al.
The Lancet. Gastroenterology & Hepatology|March 10, 2023
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 studyJason A Tye-Din, A James M Daveson, Gautam Goel, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2024
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialA James M Daveson, Richard Stubbs, Thomas M Polasek, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Best Practice & Research. Clinical Gastroenterology|June 19, 2012
Small bowel endoscopy and coeliac diseaseA James M Daveson, Robert P Anderson
Alimentary Pharmacology & Therapeutics|August 14, 2019
Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac diseaseKenneth E Truitt, A James M Daveson, Hooi C Ee, et al.
Internal Medicine Journal|December 29, 2022
High incidence of inflammatory bowel disease in Northern Australia: a prospective community population-based Australian incidence study in the Mackay-Isaac-Whitsunday regionAmanda Flanagan, Susan M Allsopp, Sam A O'Connor, et al.
Alimentary Pharmacology & Therapeutics|November 27, 2019
Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac diseaseA James M Daveson, Jason A Tye-Din, Gautam Goel, et al.
BMC Medicine|November 26, 2020
Patient factors influencing acute gluten reactions and cytokine release in treated coeliac diseaseJason A Tye-Din, A James M Daveson, Kaela E Goldstein, et al.
Gastroenterology|March 28, 2026
A Randomized Double-Blind, Placebo-Controlled Dose-Response Study to Assess the Gluten Threshold Dose in Celiac DiseaseA James M Daveson, Emma Craig, Alina Vitak, et al.
Ebiomedicine|December 2, 2017
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 StudyA James M Daveson, Hooi C Ee, Jane M Andrews, et al.
Alimentary Pharmacology & Therapeutics|September 5, 2019
Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac diseaseJason A Tye-Din, A James M Daveson, Hooi C Ee, et al.
The Lancet. Gastroenterology & Hepatology|March 10, 2023
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 studyJason A Tye-Din, A James M Daveson, Gautam Goel, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2024
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialA James M Daveson, Richard Stubbs, Thomas M Polasek, et al.
Pageof 1